Future Directions for the CLL Space
Carolyn Owen, MD, discusses emerging and exciting data in the chronic lymphocytic leukemia space.
Use of MRD in the CLL Space
Carolyn Owen, MD, discusses minimal residual disease as an area of research in the chronic lymphocytic leukemia space.
Frontline Ibrutinib/Venetoclax Generates Prolonged uMRD Data in CLL
Carolyn Owen, MD, discusses data from the phase 3 GLOW study which were presented at the 10th Annual Meeting of the Society of Hematologic Oncology.
Design and Goals of the Phase 3 GLOW Study for CLL
Carolyn Owen, MD, discusses the phase 3 GLOW study which evaluated fixed-duration ibrutinib and venetoclax in elderly or unfit patients with chronic lymphocytic leukemia. .
Discussing First-Line Treatments for Patients With CLL
Carolyn Owen, MD, discusses how the treatment landscape has shifted in chronic lymphocytic leukemia.
